Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lessons from RUTH.

Amos Pines

    Climacteric : the Journal of the International Menopause Society
    |September 27, 2006
    PubMed
    Summary
    This summary is machine-generated.

    The Raloxifene Use for The Heart (RUTH) trial found raloxifene had no effect on coronary artery disease (CAD) risk. Serious adverse events and limited benefits raise questions about its use for primary prevention.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Recommended measurement instruments for menopausal vasomotor symptoms: the COMMA (Core Outcomes in Menopause) consortium.

    Menopause (New York, N.Y.)·2024
    Same author

    Lessons from shaking menopausal hands.

    Menopause (New York, N.Y.)·2022
    Same author

    Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement.

    Maturitas·2021
    Same author

    Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide.

    Maturitas·2021
    Same author

    Management of urinary incontinence in postmenopausal women: An EMAS clinical guide.

    Maturitas·2020
    Same author

    The Mediterranean diet and menopausal health: An EMAS position statement.

    Maturitas·2020
    Same journal

    The International Menopause Society celebrates another milestone.

    Climacteric : the journal of the International Menopause Society·2026
    Same journal

    Impact of social determinants of health on perimenopause symptom burden: insights from the Flo app.

    Climacteric : the journal of the International Menopause Society·2026
    Same journal

    From tissue to outcome - how perioperative vaginal estrogen transforms prolapse surgery results: a systematic review and meta-analysis of clinical evidence and outcomes.

    Climacteric : the journal of the International Menopause Society·2026
    Same journal

    Mapping menopause education for healthcare professionals: a scoping review.

    Climacteric : the journal of the International Menopause Society·2026
    Same journal

    Portuguese osteopaths' perceptions on the management of musculoskeletal conditions in menopausal women.

    Climacteric : the journal of the International Menopause Society·2026
    Same journal

    Perimenopausal migraine: a narrative review.

    Climacteric : the journal of the International Menopause Society·2026
    See all related articles

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology
    • Geriatrics

    Background:

    • The Raloxifene Use for The Heart (RUTH) trial evaluated raloxifene's cardioprotective potential in elderly women with existing or at-risk coronary artery disease (CAD).
    • Raloxifene, a selective estrogen receptor modulator, is used for osteoporosis prevention and breast cancer risk reduction.

    Discussion:

    • RUTH trial results showed raloxifene did not reduce CAD risk over 5.6 years.
    • The study identified significant adverse events, including stroke and venous thromboembolism.
    • The absolute risk reduction for breast cancer and vertebral fractures was minimal (1 per 1,000 women/year).

    Key Insights:

    • Raloxifene demonstrated a neutral effect on coronary artery disease risk in the studied population.
    • The incidence of serious adverse events necessitates a careful risk-benefit assessment.

    Related Experiment Videos

  • The limited absolute benefit in preventing fractures and breast cancer warrants pharmacoeconomic evaluation.

    • Outlook:

    • Further research is needed to clarify the role of raloxifene in specific patient subgroups.
    • The findings suggest a re-evaluation of raloxifene's primary prevention indications.
    • Pharmacoeconomic analyses are crucial for determining the clinical utility of raloxifene given its risk profile.